Oklahoma's Medicaid MU payments over by $800K

The Oklahoma Health Care Authority (OHCA) has made incorrect Medicaid Meaningful Use incentive payments to healthcare professionals totaling $888,250, according to a report from the Department of Health and Human Services' Office of Inspector General (OIG).

The OIG found that $888,250 was paid to 47 hospital-based professionals after the agency misinterpreted the time frame for determining hospital-based status. OHCA also claimed $127,500 more than it paid because it mistakenly included six duplicate payments in its report to the Centers for Medicare & Medicaid Services (CMS). The data also did not include a $21,250 payment because of data transmission problems to the repository and lack of reconciliation procedures. 

The OIG recommended that the state refund the federal government the $888,250 in overpayments as well as the $127,500 in over-reported payments, ensure that the $21,250 is successfully transmitted and establish procedures to reconcile the CMS report with the National Level Registry.

The OIG has audited seven other state agencies and found incorrect Medicaid EHR incentive payments in Louisiana and Massachusetts in 2014 and in Arkansas and Texas earlier this year.

Access the report.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup